New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 5, 2014
05:42 EDTMDT, SNN, JNJ, ZMH, SYKMedtronic offer for Smith & Nephew may bring bidding war, says Wells Fargo
Wells Fargo believes a Medtronic (MDT) takeover offer for Smith & Nephew (SNN) would make strategic and financial sense. However, Wells cautions that Smith & Nephew's "relatively small" share in hip and knee implants could put Medtronic at a competitive disadvantage to larger ortho players Johnson & Johnson (JNJ) and Zimmer (ZMH). The firm thinks a potential offer from Medtronic may prompt Stryker (SYK) to reconsider Smith & Nephew, potentially resulting in a bidding war.
News For MDT;SNN;JNJ;ZMH;SYK From The Last 14 Days
Check below for free stories on MDT;SNN;JNJ;ZMH;SYK the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
August 26, 2014
05:54 EDTMDTMedtronic acquires Sapiens SBS for $200M
Subscribe for More Information
August 25, 2014
10:03 EDTMDTMedtronic announces FDA approval of Viva CRT-P for heart failure or AV block
Subscribe for More Information
08:27 EDTJNJJanssen Affiliate Cilag acquires Covagen, terms not disclosed
Subscribe for More Information
07:03 EDTJNJVIVUS acquires patents from Janssen Pharmaceuticals
VIVUS (VVUS) announced the acquisition of a group of patents from Janssen Pharmaceuticals (JNJ) covering uses of topiramate as monotherapy and in combination with other pharmaceutical agents to treat a variety of medical conditions. Janssen has agreed to dismiss the lawsuit it brought against VIVUS on August 22, 2014 in the U.S. District Court for the District of Delaware. VIVUS will pay a one-time upfront fee and a royalty to Janssen on Qsymia product sales for an assignment of these topiramate-related patents owned by Janssen. VIVUS has an option to buy out the royalty for a predetermined amount.
August 21, 2014
05:42 EDTJNJIllumina announces strategic partnership with AstraZeneca, Sanofi, Janssen
Illumina (ILMN) announced it has formed collaborative partnerships with leading pharmaceutical companies to develop a universal next-generation sequencing, or NGS,-based oncology test system. The system will be used for clinical trials of targeted cancer therapies with a goal of developing and commercializing a multi-gene panel for therapeutic selection, resulting in a more comprehensive tool for precision medicine. Initial strategic partners include AstraZeneca (AZN), Janssen Biotech, a Johnson & Johnson (JNJ) company, and Sanofi (SNY). Illumina is working with the strategic partners to develop assays that detect and measure multiple variants simultaneously to support partners’ clinical trials, with the objectives of securing regulatory agency approvals and test commercialization. In parallel, Illumina is working with key thought leaders to set standards for NGS-based assays in routine clinical oncology practice, as well as to define regulatory frameworks to enable this new testing paradigm. Together, Illumina and its strategic partners aim to transition from single-analyte companion diagnostics to panel-based assays that select for “companion therapeutics.”
August 20, 2014
08:47 EDTMDTMedtronic valuation attractive, says Morgan Stanley
Morgan Stanley said Medtronic's (MDT) valuation is attractive given pipeline execution, margin growth and shareholder returns, and expectations for the Covidien (COV) deal to go through. Shares are Overweight rated
07:18 EDTMDTMedtronic shares have upside with or without deal, says Deutsche Bank
Deutsche Bank sees limited downside risk and significant upside potential for shares of Medtronic (MDT), with or without the pending Covidien (COV) acquisition. Deutsche says the Q1 results show improving trends and it keeps a Buy rating on Medtronic with an $85 price target.
August 19, 2014
08:40 EDTMDTMedtronic sees FY15 gross margin of 74.5%-75%, with Q2 on lower end of range
Subscribe for More Information
08:25 EDTMDTMedtronic: Negative factors in Spine segment in Q1 werre temporary
Subscribe for More Information
08:22 EDTMDTMedtronic: We will continue to pay significant US taxes following Covidien deal
Subscribe for More Information
07:19 EDTMDTMedtronic backs FY15 EPS view of $4.00-$4.10, consensus $4.04
Subscribe for More Information
07:17 EDTMDTMedtronic reports Q1 EPS 93c, consensus 92c
Reports Q1 revenue $4.27B, consensus $4.25B.
August 18, 2014
15:26 EDTMDTNotable companies reporting before tomorrow's open
Subscribe for More Information
14:49 EDTMDTMedtronic technical comments before earnings
Subscribe for More Information
13:59 EDTMDTMedtronic August weekly 63.5 straddle priced for 2% move into Q1
Subscribe for More Information
11:41 EDTJNJCubist rises after report sparks takeover interest speculation
Subscribe for More Information
10:47 EDTZMHZimmer advances following analyst upgrade
Subscribe for More Information
10:01 EDTZMHOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Achillion (ACHN) upgraded to Buy from Hold at Deutsche Bank... CNOOC (CEO) upgraded to Neutral from Underperform at Credit Suisse... Dollar General (DG) upgraded to Buy from Neutral at Sterne Agee... Equity Residential (EQR) upgraded to Hold from Underperform at Jefferies... HMS Holdings (HMSY) upgraded to Overweight from Equal Weight at First Analysis... HP (HPQ) upgraded to Buy from Neutral at Monness Crespi... Halcon Resources (HK) upgraded to Buy from Hold at MLV & Co.... KapStone (KS) upgraded to Buy from Hold at Deutsche Bank... Sportsman's Warehouse (SPWH) upgraded at RW Baird... Westlake Chemical (WLK) upgraded to Neutral from Reduce at SunTrust... WisdomTree (WETF) upgraded to Neutral from Sell at Citigroup... Zimmer (ZMH) upgraded to Outperform from Market Perform at William Blair.
07:04 EDTZMHZimmer upgraded to Outperform from Market Perform at William Blair
William Blair upgraded Zimmer Holdings to Outperform citing the recent pullback in shares and its belief the proposed Biomet acquisition will close.
06:24 EDTMDTOptions expected to be active
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use